Member Info for Coldspy

Troubled online advertising business Matomy Media Group Limited (DI) (MTMY)

Follow
jumped on announcing a shake-up to allow it to repay worried bondholders. It plans to raise £6million to £8million from shareholders, to buy the remaining 10% of subsidiary Team Internet and help pay back £24million of bonds. Matomy also said it had received two offers for Team Internet, but that it believed it could get a better price if it decided to sell the business. Shares shot up by 2p, to 7.5p.

Website: http://www.matomy.com/
Twitter Handle: https://twitter.com/MatomyGroup
Blog: http://www.matomy.com/blog/
Employees on LinkedIn: 336
Founded: 2007
HQ: Tel Aviv, Israel.
Pricing Models: CPI, CPA, CPM, CPV, CPL, CPC
Mobile App Install Tracking Partners: MobileApp Tracking by TUNE, Kochava, Adjust, AppsFlyer

Matomy Media Group is a Tel Aviv-based digital performance advertising platform, that specializes in cross-channel display, mobile, social, video, email and search campaigns. They run a multi-channel ad network, along with other offerings such as: Incentivized Virtual Currency, Domain Monetization, and Search Engine Optimization services.

The company went public in mid-2014 after having delayed their IPO for a few months — and later in the year (Oct 2014), it was announced that Publicis would be completing a transaction effectively acquiring 24.9% of Matomy.

They raised a total of $17M in venture capital prior to going public, and have made a handful of acquisitions along the way including: MediaWhiz (Jan 2013), MobAff (Jul 2013), Adquant (Oct 2013), Team Internet (Jun 2014), MobFox (Oct 2014), Optimatic (Nov 2015).

In terms of sheer numbers, they have access to over 70B impressions per month on Display, 30B impressions per month on Mobile, 600M impressions per month on Social, 2B Video Plays on Video (through 200+ managed video publishers as well as through video ad exchanges), send 14M emails per day, drive 6M Incentivized conversions per month, have monetized 30B parked domains, and have 18k registered affiliates.

They also have 5,000 active advertisers running over 18,000 live campaigns, in over 100 countries. Verticals they have an expertise in are Games, Finance, Healthcare, Dating, Insurance, Home Services, Software, Education, eCommerce, Mobile Content, Entertainment, Mobile Apps, and Utilities.

@HenryB What rumours were posted last night?

and yet 20% up today..

It's called re-rate from year lows on the expectation that a previously doomed company will be offered a lifeline and is keen to return value to stakeholders.

My wishful thinking or someone else prediction won't change the SP.
The market will decide that.

iknowverylittle, Bondholders meeting on whether or not they will approve a $10m funding so MTMY can purchse the final 10% of Team Internet from a company called Rainmaker. MTMY already own 90% of that company

To top up.

Another 20% tomorrow to finish near 12pm would be brilliant. Platform ready to spring up Monday

And 150k too

Probably held through the day to fill these and more.

Then let it go once filled.

Probably more orders being worked on now. Can sell volume

Another 100k BUY

I think most expecting positive news on Monday.

Just enjoying the re-rate here

Well done anyone who did well so far and sold..

I'm still holding for Monday RNS

Certainly worthy of a boom

Nice to see 12p tomorrow before news on Monday of BH deal.

Then a 150% rise on the day to 30p..Asking too much? :)

Without news yes prpbably drift a little.

It's one to keep a holding in, leave them in the bottom drawer.

One day when you least expect it they'll be worth a lot of money

Sareum reaches preclinical milestone in TYK2/JAK1 inhibitor programme - Potent, selective small molecule inhibitor of TYK2/JAK1 selected for further development as a potential treatment for autoimmune diseases

Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development company, announces it has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new treatment for autoimmune diseases.

The candidate molecule, SDC-1801, demonstrated high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3), compelling activity in disease models of psoriasis and rheumatoid arthritis, the potential for once-daily oral dosing and a good early safety profile. Closely related molecules, including SAR-20347, have also shown good activity in models of inflammatory bowel disease and systemic lupus erythematosus (lupus). These attributes strongly support the progression of SDC-1801 into preclinical development and, pending satisfactory progress, advancement into human clinical trials, which could begin in 2020.

The preclinical development candidate SDC-1801 was nominated from a novel series of compounds designed and identified by Sareum following a rigorous selection process. The company is also completing its assessment of further dual TYK2/JAK1 inhibitors for the potential treatment of certain cancers and/or as a back-up to SDC-1801 and expects to nominate this candidate in the near future.

TYK2 and JAK1 are members of the Janus Kinase (JAK) family of protein kinase enzymes with roles in pro-inflammatory responses in autoimmune diseases and tumour cell proliferation in certain cancers. Members of the JAK family are the targets of several marketed and clinical-stage drugs for cancer and autoimmune diseases, although there are currently no marketed products specifically targeting TYK2.Â

Dr Tim Mitchell, CEO of Sareum, commented: "TYK2 and JAK1 have emerged in recent years as important targets for new drugs with potential to treat a broad range of autoimmune diseases. This has naturally led to some serious interest from the major pharmaceutical companies, including  Pfizer, Bristol-Myers Squibb and Celgene having their own clinical and preclinical programmes in this area. With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features. We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate."

Sareum has an ongoing co-development agreement with SRI International (Menlo Park, CA, USA) to develop TYK2 inhibitors in autoimmune diseases. Sareum retains commercialisation rights for these and other TYK2 inhibitors with profiles optimised for oncology indications.

Thanks DP888 Was here the time it went up about 1000% in 2 days Watched my £40,000 profit slowly drift away back then, eventually pressed sell lol But many sold out too early and missed the real rise

Speeding ticket here Let's see if one comes

Delayed trade 2.5 million

Back

Look how it's holding up despite the sells.

MMs happy to accumulate imo , they'll sell them back to you for 2-3p soon

Delayed 100k BUY

There have been a lot of 100k 150k buys this week.

Either it's one of us (not me) , or someone accumulating before Monday.

That's the basic structure of it, the 50m is my guesstimate for what they would need to pay for the 60% - Could be more - could be less.

TI is worth 120m plus, it gives us 15m in dividends per year, if we buy final 10% we get 20m per year in dividends.

MickR, I believe the case is that we have agreed to buy the remaining 10% (also agreed a 4.5m dollar discount from initial agreement which was 18m dollars for remaining 10%)

If we don't proceed to buy then Rainmaker has the option to buy the 90% off us at 60% of what we paid. Not the best deal but still surely a good $50m dollars for us. At M/Cap of $8m dollars, plenty upside either case.

Happy to be corrected if I have misunderstood.

BH's arent stupid, they'll stump up 10m to get back 20m by March end..

DP888 , as far as we can tell MTMY wish to raise approx $13m in total. At least $10m will be from key shareholders, and remaining on LSE.

The terms of the raise aren't clear at this point.

Some say a placing at 16p (95% above current SP) which if true is amazing

But could just be a loan/bond at 7% interest

Really not sure. Whichever option, it secures the future of MTMY and SP will respond positively